ReviewNature clinical practice. Urology2009
Photodynamic therapy for prostate cancer--a review of current status and future promise.
Review in Nature clinical practice. Urology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
99 citing papers in PubMed, 328 citations in OpenAlex.
- Vascular targeted photodynamic therapy with TOOKAD® Soluble (WST11) in localized prostate cancer: efficiency of automatic pre-treatment planning.Lasers in medical science · 2017Trial
- Histopathology of prostate tissue after vascular-targeted photodynamic therapy for localized prostate cancer.Virchows Archiv : an international journal of pathology · 2013Trial
- Redox-modulation of regulated cell death: implications for synergistic anticancer therapies.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Nano-/Nanobiotechnology-Augmented Pyroptosis in the Treatment of Triple-Negative Breast Cancer: An Updated Review.International journal of nanomedicine · 2026Review
- Polymeric Nanocarriers of a Monosubstituted Tetraphenylporphyrin Sensitizer Intended for Photodynamic Therapy and Tumor Imaging.ACS omega · 2025Article
- Reprogramming of cancer metabolism via photoresponsive nano-PROTAC enhances pyroptosis-mediated immunotherapy.Signal transduction and targeted therapy · 2025Article
- Improved Photodynamic Therapy of Hepatocellular Carcinoma via Surface-Modified Protein Nanoparticles.Pharmaceutics · 2025Article
- One-Pot Synthesis of Oxygen Vacancy-Rich Amorphous/Crystalline Heterophase CaWOAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Photodynamic therapy for the precise treatment of localized prostate cancer.Frontiers in oncology · 2025Review
- Advancements in nanotechnology-driven photodynamic and photothermal therapies: mechanistic insights and synergistic approaches for cancer treatment.RSC advances · 2024Review
- Advancing gastric cancer treatment: nanotechnology innovations and future prospects.Cell biology and toxicology · 2024Review
- Photodynamic Therapy: Past, Current, and Future.International journal of molecular sciences · 2024Review
- Enhanced cellular therapy: revolutionizing adoptive cellular therapy.Experimental hematology & oncology · 2024Review
- Co-Loading of Black Phosphorus Nanoflakes and Doxorubicin in Lysolipid Temperature-Sensitive Liposomes for Combination Therapy in Prostate Cancer.International journal of molecular sciences · 2023Article
- A modular phage vector platform for targeted photodynamic therapy of Gram-negative bacterial pathogens.iScience · 2023Article
- Shining a Light on Prostate Cancer: Photodynamic Therapy and Combination Approaches.Pharmaceutics · 2023Review
- Metal-Organic Layer Delivers 5-Aminolevulinic Acid and Porphyrin for Dual-Organelle-Targeted Photodynamic Therapy.Angewandte Chemie (International ed. in English) · 2023Article
- Effect of Photodynamic Therapy with Chlorin e6 on Canine Tumors.Life (Basel, Switzerland) · 2022Article
- Long wavelength-emissive Ru(II) metallacycle-based photosensitizer assisting in vivo bacterial diagnosis and antibacterial treatment.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Real-Time MRI-Guided Prostate Interventions.Cancers · 2022Review
39 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Debate is ongoing about the treatment of organ-confined prostate cancer, particularly in men who have low-risk disease detected by PSA screening. A balance is needed between the harms and benefits of treatment. New techniques are being developed that aim to offer similar treatment effects to current radical therapies, while reducing the associated harmful effects of these treatments. In this Review, we explore the potential of one such technique, photodynamic therapy (PDT), for the treatment of organ-confined prostate cancer. PDT uses a photosensitizing drug that is activated in the prostate by low-power laser light, delivered using optical fibers. The fibers are placed within needles in the prostate, guided by transrectal ultrasound and a perineal template. Following the activation of the photosensitizer by light, and the formation of reactive oxygen species, necrosis occurs at the site of interaction between the photosensitizer, light and oxygen. Clinical studies are underway to investigate the use of PDT for primary and salvage treatment of organ-confined prostate cancer. We review these studies, the potential strategies for enhanced photodynamic effects, and the current limitations of PDT for prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.